Swiss National Bank acquired a new stake in Myovant Sciences Ltd (NASDAQ:MYOV) during the second quarter, according to its most recent filing with the SEC. The firm acquired 25,100 shares of the company’s stock, valued at approximately $294,000.
A number of other large investors have also recently bought and sold shares of MYOV. Quantitative Systematic Strategies LLC purchased a new position in Myovant Sciences in the 2nd quarter valued at $165,000. Wells Fargo & Company MN grew its position in Myovant Sciences by 331.9% in the 1st quarter. Wells Fargo & Company MN now owns 16,527 shares of the company’s stock valued at $194,000 after buying an additional 12,700 shares during the last quarter. Bank of New York Mellon Corp grew its position in Myovant Sciences by 36.3% in the 1st quarter. Bank of New York Mellon Corp now owns 23,784 shares of the company’s stock valued at $279,000 after buying an additional 6,330 shares during the last quarter. LMR Partners LLP purchased a new position in Myovant Sciences in the 2nd quarter valued at $320,000. Finally, JPMorgan Chase & Co. grew its position in Myovant Sciences by 30.6% in the 1st quarter. JPMorgan Chase & Co. now owns 83,070 shares of the company’s stock valued at $975,000 after buying an additional 19,474 shares during the last quarter.
COPYRIGHT VIOLATION WARNING: “25,100 Shares in Myovant Sciences Ltd (MYOV) Acquired by Swiss National Bank” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/13/swiss-national-bank-purchases-new-position-in-myovant-sciences-ltd-myov.html.
A number of equities analysts recently weighed in on MYOV shares. Zacks Investment Research upgraded shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Robert W. Baird reiterated a “buy” rating and issued a $20.00 price objective on shares of Myovant Sciences in a research report on Friday. Evercore ISI started coverage on shares of Myovant Sciences in a research report on Wednesday, August 16th. They issued an “outperform” rating on the stock. JMP Securities reiterated an “outperform” rating and issued a $25.00 price objective (up from $23.00) on shares of Myovant Sciences in a research report on Wednesday, October 4th. Finally, Cowen and Company restated a “buy” rating on shares of Myovant Sciences in a research report on Tuesday, October 3rd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $20.00.
Shares of Myovant Sciences Ltd (NASDAQ:MYOV) traded down $0.09 during midday trading on Monday, hitting $14.12. 19,082 shares of the company’s stock traded hands, compared to its average volume of 35,857. Myovant Sciences Ltd has a 52 week low of $9.92 and a 52 week high of $18.85.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.